Recursion Q2 Revenue Misses, Loss Wider Than Expected; Cuts Expense Outlook
RXRX is trading near its 52-week low of $2.77 (9.4% above the low).
Summary
Recursion's Q2 revenue of $7.3M missed consensus by 39%, driven by declining collaboration revenue from Roche/Genentech as projects completed. Net loss of $131M was wider than the $119M analysts expected, despite cost cuts. The company lowered its 2026 cash operating expense guidance to under $375M from under $390M, extending its cash runway into early 2028. Two key pipeline catalysts are on deck for 2H26: the start of a Phase 1/2 trial for REC-7735 and a registrational path update for REC-4881. The revenue miss and wider loss raise concerns about near-term growth, but the extended runway and upcoming catalysts could shift sentiment if positive.
At the time of this announcement, RXRX was trading at $3.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $2.77 to $7.18. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.